A systematic review of the international prevalence of BRCA mutation in breast cancer

References

• Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018 [press release]. Geneva, Switzerland: International Agency for Research on Cancer; September 12, 2018 https://www.who.int/cancer/PRGlobocanFinal.pdf. Accessed June 10, 2019.
   Google Scholar
• Engel C, Fischer C. Breast cancer risks and risk prediction models. Breast Care (Basel). 2015;10(1):7–12. doi:10.1159/00037660025960719
   PubMed Web of Science ®Google Scholar
• Greenup R, Buchanan A, Lorizio W, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20(10):3254–3258. doi:10.1245/s10434-013-3205-123975317
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2018 - October 3, 2017 [Internet]. Fort Washington, PA: NCCN; 2017 Accessed 1215, 2017 Available from: https://www.nccn.org/
   Google Scholar
• Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25(43):5864–5874. doi:10.1038/sj.onc.120987416998501
   PubMed Web of Science ®Google Scholar
• Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188. doi:10.1186/s12916-015-0425-126268938
   PubMed Web of Science ®Google Scholar
• Paluch-Shimon S, Friedman E, Berger R, et al. Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. Breast Cancer Res Treat. 2016;157(1):157–165. doi:10.1007/s10549-016-3800-527113739
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE Clinical Guideline CG164 [Internet]. Manchester: NICE; 2013 Accessed 1130, 2017 Available from: nice.org.uk/guidance/cg164
   Google Scholar
• Cancer Australia. Recommendations for the Management of Early Breast Cancer in Women with an Identified BRCA1 or BRCA2 Gene Mutation or at High Risk of a Gene Mutation [Internet]. Surry Hills: Australian Government, Cancer Australia; 2014 Accessed 15, 2018 Available from: http://guidelines.canceraustralia.gov.au/guidelines/gene_mutation/index.php
   Google Scholar
• De Felice F, Marchetti C, Musella A, et al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Ann Surg Oncol. 2015;22(9):2876–2880. doi:10.1245/s10434-015-4532-125808098
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. Version 5.1.0. London, UK: The Cochrane Collaboration; 2011 Updated March 2011. Accessed 323, 2011 Available from: http://handbook.cochrane.org/
   Google Scholar
• Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care [Internet]. York: University of York; 2009 Accessed 323, 2011 Available from: http://www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm
   Google Scholar
• Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and incidence data. Int J Evid Based Healthc. 2015;13(3):147–153. doi:10.1097/XEB.0000000000000054
   Google Scholar
• Pal T, Bonner D, Cragun D, et al. A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer. 2015;121(23):4173–4180. doi:10.1002/cncr.2964526287763
   PubMed Web of Science ®Google Scholar
• Park B, Sohn JY, Yoon KA, et al. Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients. Breast Cancer Res Treat. 2017;163(1):139–150. doi:10.1007/s10549-017-4142-728205045
   PubMed Web of Science ®Google Scholar
• Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121(1):25–33. doi:10.1002/cncr.2901025186627
   PubMed Web of Science ®Google Scholar
• Asleh-Aburaya K, Fried G. Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience. Springerplus. 2015;4:132. doi:10.1186/s40064-015-0900-325825688
   PubMedGoogle Scholar
• de Juan Jimenez I, Esteban Cardenosa E, Palanca Suela S, et al. Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population. Fam Cancer. 2012;11(1):49–56. doi:10.1007/s10689-011-9481-721918853
   PubMed Web of Science ®Google Scholar
• Duffy J, Greening S, Warwick L, Tucker K, Creighton B. An Australian perspective of genetic testing in breast cancers diagnosed under age 31. Curr Oncol. 2012;19(2):e106.
   Google Scholar
• Eccles DM, Li N, Handwerker R, et al. Genetic testing in a cohort of young patients with HER2-amplified breast cancer. Ann Oncol. 2016;27(3):467–473. doi:10.1093/annonc/mdv59226681682
   PubMed Web of Science ®Google Scholar
• Ellsworth RE, Lovejoy LA, Shriver C. Assessment of the hereditary component in 94 cancer predisposition genes to triple negative breast cancer. Presented at 40th Annual San Antonio Breast Cancer Symposium [Internet]; 12 5–9, 2017; San Antonio, Texas, USA: P4–07–01 Accessed 38, 2018 Available from: https://www.sabcs.org/Resources#AbstractsPDF
   Google Scholar
• Emborgo T, Muse KI, Bednar E, et al. Universal BRCA testing and family outreach for women with triple negative breast cancer. Cancer Res. 2016;76(4):P2–09–08.
   Google Scholar
• Garber JE, Tung NM, Elkin EP, et al. Predisposing germline mutations in a clinic based breast cancer (BC) population. Cancer Res. 2016;76(4):P1–08–07.
   Google Scholar
• Gonzalez-Rivera M, Lobo M, Lopez-Tarruella S, et al. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. [Erratum appears in Breast Cancer Res Treat. 2017;165(2):471. PMID: 28721639. doi:10.1007/s10549-017-4396-0]. Breast Cancer Res Treat. 2016;156(3):507–515. doi:10.1007/s10549-016-3792-127083178
   PubMed Web of Science ®Google Scholar
• Guerra YC, Sand S, Correa MC, et al. Genetic, clinical and pathological characteristics of BRCA-associated breast cancer (BC) in Hispanic patients in the United States (US) and Latin America (LatAm). J Clin Oncol. 2017;35(15 suppl):1539. doi:10.1200/JCO.2017.35.15_suppl.1539
   Web of Science ®Google Scholar
• Kim H, Cho DY, Choi DH, et al. Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat. 2012;134(3):1315–1326. doi:10.1007/s10549-012-2159-522798144
   PubMed Web of Science ®Google Scholar
• Kitagawa H, Yagata H, Yoshida A, Nakano E, Yoshino M, Yamauchi H. The prevalence of BRCA mutations among patients with triple-negative breast cancer. Curr Oncol. 2014;21(2):e388.
   Google Scholar
• Lee AS, Kang EY, Baek H, Chae S, Kim EK, Kim SW. Evaluation of BRCA1/2 mutation prevalence in Korean women with triple-negative breast cancer. Ann Oncol. 2015;26(Suppl 9):ix16. doi:10.1093/annonc/mdv383
   Web of Science ®Google Scholar
• Musolino A, Bella MA, Michiara M, et al. BRCA status, molecular profile and clinical variables in primary bilateral breast cancers: a population-based cancer registry study. Ann Oncol. 2012;23:ix175–ix176.
   Web of Science ®Google Scholar
• Pal T, Bonner D, Cragun D, et al. Proportion of BRCA mutation frequency in young black women with breast cancer. J Clin Oncol. 2014;15(Suppl):1506. doi:10.1200/jco.2014.32.15_suppl.1506
   Google Scholar
• Polonikov A, Aristova I, Leitanthem W, et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients in Russia. Ann Acad Med Singapore. 2015;44(10 Suppl 1):S324.
   Google Scholar
• Robertson L, Hanson H, Seal S, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012;106(6):1234–1238. doi:10.1038/bjc.2012.3122333603
   PubMed Web of Science ®Google Scholar
• Rummel S, Varner E, Shriver CD, Ellsworth RE. Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat. 2013;137(1):119–125. doi:10.1007/s10549-012-2348-223192404
   PubMed Web of Science ®Google Scholar
• Rummel SK, Lovejoy L, Shriver CD, Ellsworth RE. Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer. Breast Cancer Res Treat. 2017;164(3):593–601. doi:10.1007/s10549-017-4291-828503720
   PubMed Web of Science ®Google Scholar
• Sanford RA, Song J, Gutierrez-Barrera AM, et al. Incidence of germline BRCA mutation in patients with ER-low positive/PR negative/HER-2 neu negative tumors. J Clin Oncol. 2014;26(Suppl):2. doi:10.1200/jco.2014.32.26_suppl.2
   Web of Science ®Google Scholar
• Skandan SP. 5 year overall survival of triple negative breast cancer: a single institution experience. J Clin Oncol. 2016;34(15 Suppl):e12580. doi:10.1200/JCO.2016.34.15_suppl.e12580
   Web of Science ®Google Scholar
• Son BH, Ahn SH, Kim SW, et al. Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Res Treat. 2012;133(3):1143–1152. doi:10.1007/s10549-012-2001-022382806
   PubMed Web of Science ®Google Scholar
• Vanstone M, Chow W, Lester L, Ainsworth P, Nisker J, Brackstone M. Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario. Can Fam Physician. 2012;58(5):e258–e266.22734169
   PubMed Web of Science ®Google Scholar
• Vidula N, Isakoff SJ, Niemierko A, et al. Somatic BRCA mutation detection by circulating tumor DNA analysis in patients with metastatic breast cancer: incidence and association with tumor genotyping results, germline BRCA mutation status, and clinical outcomes. Presented at 40th Annual San Antonio Breast Cancer Symposium; 12 5–9, 2017; San Antonio, Texas, USA: PD1–13. [Internet]. Accessed 38, 2018 Available from: https://www.sabcs.org/Resources#AbstractsPDF
   Google Scholar
• Yoon KA, Park B, Lee BI, Yang MJ, Kong SY, Lee ES. Clinically significant unclassified variants in BRCA1 and BRCA2 genes among Korean breast cancer patients. Cancer Res Treat. 2017;49(3):627–634. doi:10.4143/crt.2016.29227658390
   PubMed Web of Science ®Google Scholar
• Kang E, Seong MW, Park SK, et al. The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Res Treat. 2015;151(1):157–168. doi:10.1007/s10549-015-3377-425863477
   PubMed Web of Science ®Google Scholar
• Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145(3):707–714. doi:10.1007/s10549-014-2980-024807107
   PubMed Web of Science ®Google Scholar
• Keung YK, Hu A, Yeung A, Chan A, Hu E. Higher prevalence of BRCA2 mutations among Chinese breast cancer patients in a community oncology clinic. J Clin Oncol. 2012;15(Suppl):12017.
   Google Scholar
• Dagan E, Gershoni-Baruch R, Kurolap A, Fried G. Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up. Eur J Cancer Care. 2017;26:6. doi:10.1111/ecc.12594
   Web of Science ®Google Scholar
• Bayraktar S, Gutierrez-Barrera AM, Lin H, et al. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis. 2013;30(5):631–642. doi:10.1007/s10585-013-9567-823370825
   PubMed Web of Science ®Google Scholar
• Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460–1468. doi:10.1200/JCO.2015.65.074726976419
   PubMed Web of Science ®Google Scholar
• Cherdyntseva NV, Pisareva LF, Ivanova AA, et al. [Ethnic aspects of hereditary breast cancer in the region of Siberia]. Vestn Ross Akad Med Nauk. 2014;(11–12):72–79. doi:10.15690/vramn.v69i11-12.118625971130
   PubMedGoogle Scholar
• Ellsworth RE, Rummel S, Varner E, Shriver CD. Evaluation of BRCA1 mutations in patients with triple negative breast cancer. Cancer Res. 2012;72(8 Suppl):68.
   Web of Science ®Google Scholar
• Ghadirian P, Robidoux A, Nassif E, et al. Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal. Clin Genet. 2014;85(1):31–35. doi:10.1111/cge.1217423621881
   PubMed Web of Science ®Google Scholar
• Stadler ZK, Salo-Mullen E, Patil SM, et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer. 2012;118(2):493–499. doi:10.1002/cncr.2619121598239
   PubMed Web of Science ®Google Scholar
• Weitzel JN, Clague J, Martir-Negron A, et al. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the clinical cancer genetics community research network. [Erratum appears in J Clin Oncol. 2013;31(13):1702]. J Clin Oncol. 2013;31(2):210–216. doi:10.1200/JCO.2011.41.002723233716
   PubMed Web of Science ®Google Scholar
• Noh JM, Han BK, Choi DH, et al. Association between BRCA mutation status, pathological findings, and magnetic resonance imaging features in patients with breast cancer at risk for the mutation. J Breast Cancer. 2013;16(3):308–314. doi:10.4048/jbc.2013.16.3.30824155760
   PubMed Web of Science ®Google Scholar
• Pal T, Bonner D, Kim J, et al. Early onset breast cancer in a registry-based sample of African-American women: BRCA mutation prevalence, and other personal and system-level clinical characteristics. Breast J. 2013;19(2):189–192. doi:10.1111/tbj.1208323320992
   PubMed Web of Science ®Google Scholar
• Pal T, Bonner D, Cragun D, et al. BRCA sequencing and large rearrangement testing in young Black women with breast cancer. J Community Genet. 2014;5(2):157–165. doi:10.1007/s12687-013-0166-924013928
   PubMedGoogle Scholar
• Sohn JY, Park B, Yoon KA, et al. Prevalence of BRCA1 and BRCA2 small mutation and large genomic rearrangements in breast cancer patients visiting a genetic counseling clinic. Cancer Res. 2016;76(14):3474. doi:10.1158/0008-5472.CAN-16-0584
   Web of Science ®Google Scholar
• Rahman N, Turnbull A, George A, Strydom A, Kemp Z. Using cancer status is better, simpler and more cost-effective than family history in determining breast cancer genetic testing eligibility. Presented at American Society of Human Genetics Annual Meeting 2017; 10 17–21, 2017; Orlando, FL [Internet]. Accessed 27, 2018 Available from: https://ep70.eventpilotadmin.com/web/page.php?page=IntHtml&project=ASHG17&id=170121508
   Google Scholar
• Petersen L, Aubry S, Burgess K, Rao R, Kopkash K, Madrigrano A. Are triple negative breast cancer patients screened for BRCA mutations according to NCCN guidelines? Ann Surg Oncol. 2016;23(1SUPPL. 1):S67–S68.
   Google Scholar
• Pal T, Bonner D, Kim J, et al. BRCA mutations and factors associated with surgery type in a registry-based sample of young black women with invasive breast cancer. Curr Oncol. 2012;19(2):e99.
   Google Scholar
• Biskupiak JE, Telford C, Yoo M, et al. Evaluation of women with BRCA mutations and breast cancer tested at an NCI designated comprehensive cancer center: a cost of illness estimation. Cancer Res. 2017;77(4 Suppl):P3-12-03. doi:10.1158/1538-7445.SABCS16-P3-12-03.
   Web of Science ®Google Scholar
• Eccles DM, Copson ER, Maishman T, et al. Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH). Cancer Res. 2017;77(4 Suppl):S2-03. doi:10.1158-7445.SABCS16-S2-03.
   Google Scholar
• Susswein LR, Marshall ML, Nusbaum R, et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med. 2016;18(8):823–832. doi:10.1038/gim.2015.16626681312
   PubMed Web of Science ®Google Scholar
• Buys SS, Sandbach JF, Gammon A, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721–1730. doi:10.1002/cncr.3049828085182
   PubMed Web of Science ®Google Scholar
• Rhiem K, Engel C, Engel J, et al. BRCA1/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer. J Clin Oncol. 2016;34(15 Suppl):1090. doi:10.1200/JCO.2016.34.15_suppl.1090
   Web of Science ®Google Scholar
• Welinsky S, Becker AE, Aronson A, Hernandez YG, Soper E, Lucas AL. No increase in prevalence of pancreatic cysts in BRCA1 or BRCA2 mutation carriers with breast cancer. Gastroenterology. 2016;150(4 Suppl 1):S233. doi:10.1016/S0016-5085(16)30853-8
   Web of Science ®Google Scholar
• Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118(11):2787–2795. doi:10.1002/cncr.2657622614657
   PubMed Web of Science ®Google Scholar
• Beck A, Yuan H, Imperiale-Hagerman P, et al. Adhering to the guidelines: rates of BRCA mutation using NCCN genetic testing criteria. Ann Surg Oncol. 2017;24(2):257048.
   Google Scholar
• Seong MW, Kim KH, Chung IY, et al. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients. Breast Cancer Res Treat. 2014;146(1):63–69. doi:10.1007/s10549-014-3006-724894343
   PubMed Web of Science ®Google Scholar
• Lolas Hamameh S, Renbaum P, Kamal L, et al. Genomic analysis of inherited breast cancer among Palestinian women: genetic heterogeneity and a founder mutation in TP53. Int J Cancer. 2017;141(4):750–756. doi:10.1002/ijc.3077128486781
   PubMed Web of Science ®Google Scholar
• Andres R, Pajares I, Balmana J, et al. Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC). Clin Transl Oncol. 2014;16(3):280–284. doi:10.1007/s12094-013-1070-923982851
   PubMed Web of Science ®Google Scholar
• Ross JL, Woodson AH, Gutierrez Barrera AM, Litton JK, Arun B. Multi-gene panel testing results in patients with multiple breast cancer primaries. Presented at 40th Annual San Antonio Breast Cancer Symposium; 12 5–9, 2017; San Antonio, Texas, USA: PD1–D10. [Internet]. Accessed 38, 2018 Available from: https://www.sabcs.org/Resources#AbstractsPDF
   Google Scholar
• Jung J, Kang E, Gwak JM, et al. Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients. Curr Oncol. 2016;23(5):298–303. doi:10.3747/co.23.305427803593
   PubMed Web of Science ®Google Scholar
• Tunon De Lara C, Bonnet F, Debled M, et al. Rapid germline BRCA screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy. Cancer Res. 2017;77(4Suppl):P5–16–23.
   Google Scholar
• Zugazagoitia J, Perez-Segura P, Manzano A, et al. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers. Breast Cancer Res Treat. 2014;148(2):415–421. doi:10.1007/s10549-014-3167-425342642
   PubMed Web of Science ®Google Scholar
• De La Cruz J, Andre F, Harrell RK, et al. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. Hum Pathol. 2012;43(11):1932–1939. doi:10.1016/j.humpath.2012.02.00222591913
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457. doi:10.1016/S0140-6736(07)61602-X18064739
   PubMed Web of Science ®Google Scholar
• Sanford RA, Song J, Gutierrez-Barrera AM, et al. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015;121(19):3422–3427. doi:10.1002/cncr.2957226280679
   PubMed Web of Science ®Google Scholar
• Palomba G, Budroni M, Olmeo N, et al. Triple-negative breast cancer frequency and type of BRCA mutation: clues from Sardinia. Oncol Lett. 2014;7(4):948–952. doi:10.3892/ol.2014.183424944648
   PubMed Web of Science ®Google Scholar
• Kast K, Rhiem K, Wappenschmidt B, et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. 2016;53(7):465–471. doi:10.1136/jmedgenet-2015-10367226928436
   PubMed Web of Science ®Google Scholar
• Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304–311. doi:10.1200/JCO.2014.57.141425452441
   PubMed Web of Science ®Google Scholar
• Meynard G, Villanueva C, Thiery-Vuillemin A, et al. 284P Real-life study of BRCA genetic screening in metastatic breast cancer. Ann Oncol. 2017;28(suppl_5):mdx365.047. doi:10.1093/annonc/mdx075
   Web of Science ®Google Scholar
• Fasching PA, Hu C, Hart SN, et al. Cancer predisposition genes in metastatic breast cancer – association with metastatic pattern, prognosis, patient and tumor characteristics. Presented at 40th Annual San Antonio Breast Cancer Symposium; 12 5–9, 2017; San Antonio, Texas, USA: PD1–D2 [Internet]. Accessed 38, 2018 Available from: https://www.sabcs.org/Resources#AbstractsPDF
   Google Scholar
• Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(1):71–80. doi:10.1007/s10549-015-3293-725682074
   PubMed Web of Science ®Google Scholar
• Nelson HD, Fu R, Goddard K, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation: Evidence Synthesis No. 101 AHRQ Publication No. 12-05164-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2013 Available from https://www.ncbi.nlm.nih.gov/books/NBK179201/pdf/Bookshelf_NBK179201.pdf
   Google Scholar
• Han SA, Kim SW, Kang E, et al. The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study. Fam Cancer. 2013;12(1):75–81. doi:10.1007/s10689-012-9578-723131904
   PubMed Web of Science ®Google Scholar
• Kurian AW, Ward KC, Howlader N, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019;37(15):1305–1315. doi:10.1200/JCO.18.01854
   Web of Science ®Google Scholar
• Tun NM, Villani G, Ong K, Yoe L, Bo ZM. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet. 2014;85(1):43–48. doi:10.1111/cge.1227024000781
   PubMed Web of Science ®Google Scholar
• Loi M, Olmetto E, Desideri I, et al. 187 - BRCA1/2 mutation in breast cancer: biological aspects, patterns of care and impact on outcome in a monoinstitutional cohort. Eur J Cancer. 2017;72(Supplement 1):S19–S19. doi:10.1016/S0959-8049(17)30141-7
   Web of Science ®Google Scholar